Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) Enterprise Value: 2009-2025

Historic Enterprise Value for Ani Pharmaceuticals (ANIP) over the last 17 years, with Sep 2025 value amounting to $1.7 billion.

  • Ani Pharmaceuticals' Enterprise Value rose 55.37% to $1.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year increase of 188.37%. This contributed to the annual value of $1.0 billion for FY2024, which is 12.34% up from last year.
  • Latest data reveals that Ani Pharmaceuticals reported Enterprise Value of $1.7 billion as of Q3 2025, which was up 44.28% from $1.2 billion recorded in Q2 2025.
  • Ani Pharmaceuticals' Enterprise Value's 5-year high stood at $1.7 billion during Q3 2025, with a 5-year trough of $403.6 million in Q3 2021.
  • In the last 3 years, Ani Pharmaceuticals' Enterprise Value had a median value of $1.1 billion in 2024 and averaged $1.1 billion.
  • As far as peak fluctuations go, Ani Pharmaceuticals' Enterprise Value dropped by 10.79% in 2021, and later spiked by 97.35% in 2023.
  • Quarterly analysis of 5 years shows Ani Pharmaceuticals' Enterprise Value stood at $482.3 million in 2021, then skyrocketed by 34.64% to $649.4 million in 2022, then surged by 39.49% to $905.8 million in 2023, then grew by 12.34% to $1.0 billion in 2024, then surged by 55.37% to $1.7 billion in 2025.
  • Its Enterprise Value was $1.7 billion in Q3 2025, compared to $1.2 billion in Q2 2025 and $1.3 billion in Q1 2025.